Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 18/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22361680 | 1.00 | KIF11 (0.61) | KIF11 | |
| SCHEMBL1905808 | 1.00 | KIF11 (0.61) | KIF11 | |
| SCHEMBL1268931 | 0.96 | KIF11 (0.60) | KIF11 | |
| SCHEMBL2238290 | 0.96 | KIF11 (0.60) | KIF11 | |
| SCHEMBL30148489 | 0.96 | KIF11 (0.60) | KIF11 | |
| SCHEMBL21690007 | 0.88 | KIF11 (0.54) | KIF11 | |
| SCHEMBL29634957 | 0.87 | KIF11 (0.49) | KIF11 | |
| SCHEMBL29516472 | 0.85 | KIF11 (0.61) | KIF11 | |
| SCHEMBL12475661 | 0.83 | KIF11 (0.62) | KIF11 | |
| SCHEMBL12475659 | 0.83 | KIF11 (0.62) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118879592-A | Unnatural base pair compositions and methods of use | 斯克利普斯研究所 | 2024-11-01 | — | — | CN | disclosed |
| CN-112105627-B | Unnatural base pair compositions and methods of use | 斯克利普斯研究所 | 2024-07-02 | — | — | CN | disclosed |
| CN-118139868-A | Orally bioavailable nucleoside analogs | 维纳拓尔斯制药公司 | 2024-06-04 | — | — | CN | disclosed |
| WO-2024083220-A1 | LIGAND-OLIGONUCLEOTIDE CONJUGATE AND LINKER FOR CONJUGATE | 上海京新生物医药有限公司 | 2024-04-25 | — | — | WO | disclosed |
| EP-4355755-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | Venatorx Pharmaceuticals, Inc. (US) | 2024-04-24 | — | — | EP | disclosed |
| US-11957787-B2 | Wnt compositions and methods for purification | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-04-16 | — | — | US | disclosed |
| US-20240117363-A1 | PRODUCTION OF UNNATURAL NUCLEOTIDES USING A CRISPR/CAS9 SYSTEM | THE SCRIPPS RESEARCH INSTITUTE | 2024-04-11 | — | — | US | disclosed |
| US-11879145-B2 | Reagents and methods for replication, transcription, and translation in semi-synthetic organisms | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-01-23 | — | — | US | disclosed |
| CN-111182880-B | WNT compositions and process from serum-free culture conditions | 安卡萨再生疗法公司 | 2024-01-09 | — | — | CN | disclosed |
| US-11761007-B2 | Production of unnatural nucleotides using a CRISPR/Cas9 system | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-09-19 | — | — | US | disclosed |
| WO-2015153402-A1 | PEPTIDE FRAGMENTS OF NETRIN-1 AND COMPOSITIONS AND METHODS THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-10-08 | — | — | WO | disclosed |
| US-9096684-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20150183825-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2015-07-02 | — | — | US | disclosed |
| WO-2015051122-A2 | WNT COMPOSITIONS AND METHODS FOR PURIFICATION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2015-04-09 | — | — | WO | disclosed |
| US-8987414-B2 | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20150051155-A1 | PEPTIDOMIMETIC MACROCYCLES | HOFFMANN-LA ROCHE, INC. | 2015-02-19 | — | — | US | disclosed |
| US-8927500-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20130274205-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2013-10-17 | — | — | US | disclosed |
| US-20130210745-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130123169-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11957787-B2 | Wnt compositions and methods for purification | WNT3A, CTNNBL1, WNT1 | KIF11 1314/4885 |
| US-20150051155-A1 | PEPTIDOMIMETIC MACROCYCLES | TP53, MDM2, MDM4 | KIF11 1661/4885 |
| US-20130123169-A1 | PEPTIDOMIMETIC MACROCYCLES | GHRHR, GHSR, GHITM | KIF11 1600/4885 |
| US-11879145-B2 | Reagents and methods for replication, transcription, and translation in semi-synthetic organisms | RNGTT, MAX, POLRMT | KIF11 3760/4885 |
| US-20130210745-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | IL33, TPR, CDC37 | KIF11 3039/4885 |
| US-20130274205-A1 | PEPTIDOMIMETIC MACROCYCLES | PROKR1, GLP1R, PROKR2 | KIF11 2465/4885 |
| US-20150183825-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | IL33, TPR, CDC37 | KIF11 3039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.